ALT Form 3 — Linda M. Richardson Reports Officer Role; No Securities Owned

Rhea-AI Filing Summary

Altimmune, Inc. (ALT) Form 3: Linda M. Richardson submitted an initial Section 16 Form 3 reporting relationship to Altimmune as Chief Commercial Officer and a director-level officer. The filing states the date of the event as 09/16/2025 and the Form was signed by an attorney-in-fact on 09/17/2025. The Form explicitly notes no securities are beneficially owned by the reporting person and includes Exhibit 24 (Power of Attorney).

Insights

Corporate Governance Expert

TL;DR: Routine initial Section 16 filing noting officer status and no beneficial ownership.

The Form 3 documents a standard initial Section 16 disclosure for an officer-level reporting person. It clarifies Linda M. Richardson's role as Chief Commercial Officer and that she currently holds no beneficial ownership in Altimmune common stock. The inclusion of Exhibit 24 indicates an executed power of attorney was used to file the form. From a governance standpoint, this is a routine compliance filing that establishes reporting obligations going forward.

Securities Compliance Analyst

TL;DR: Compliance filing appears complete and indicates no reportable holdings at time of event.

The filing identifies the event date (09/16/2025) and shows the Form was signed by an attorney-in-fact on 09/17/2025. The explicit statement that "No securities are beneficially owned" means there are no current Section 16 reportable positions to disclose. This Form 3 therefore establishes the reporting record for future transactions but conveys no current holdings or derivative exposures.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Richardson Linda M

(Last) (First) (Middle)

C/O ALTIMMUNE, INC.

910 CLOPPER ROAD, SUITE 201S

(Street)

GAITHERSBURG MD 20878

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
09/16/2025

3. Issuer Name and Ticker or Trading Symbol
Altimmune, Inc. [ ALT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Gregory Weaver, as Attorney-in-Fact	09/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Altimmune (ALT) Form 3 filed by Linda M. Richardson disclose?

It discloses Linda M. Richardson's relationship to Altimmune as Chief Commercial Officer and that no securities are beneficially owned as of the 09/16/2025 event date.

When was the Form 3 event date and filing signed for ALT?

The event date is 09/16/2025 and the Form shows a signature by an attorney-in-fact dated 09/17/2025.

Does the Form 3 report any stock or option holdings for the reporting person?

No. The Form explicitly states "No securities are beneficially owned."

What is Exhibit 24 referenced in the Form 3?

Exhibit 24 is a Power of Attorney, which the filing includes to authorize the attorney-in-fact to sign the Form on behalf of the reporting person.

Is this Form 3 a joint filing or by a single reporting person?

The filing is by one reporting person, as indicated on the form.